pharma · Alopecia areata · Multiple myeloma
First Biotech (Australia)
Pfizer Australia Pty Ltd
Pfizer Australia Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Alopecia areata, Multiple myeloma, Heart failure, Acute Migraine (with or without aura), Transthyretin amyloidosi
Company details
- Status
- Public
- HQ
- Norwest House, 710 Collins Street, Melbourne, VIC 3008, AU
- Founded
- 2017
- Employees
- 2
- Programs
- 126
- Drugs
- 208
- Patents
- 0
C5911001 - SGN-CD25V
Phase 1 · other · Advanced lymphomas (classic Hodgkin lymphoma [cHL], peripheral T cell lymphoma [PTCL], and diffuse large B cell lymphoma [DLBCL]), Solid tumors (eg, NSCLC, HNSCC, and melanoma)
C5911001 - SGN-CD25V for Advanced lymphomas (classic Hodgkin lymphoma [cHL], peripheral T cell lymphoma [PTCL], and diffuse large B cell lymphoma [DLBCL]), Solid tumors (eg, NSCLC, HNSCC, and melanoma) is a Phase 1 program (other) at Pfizer Australia Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code C5911001 - SGN-CD25V
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pfizer Australia Pty Ltd
- Phase
- Phase 1
- Modality
- other
- Indication
- Advanced lymphomas (classic Hodgkin lymphoma [cHL], peripheral T cell lymphoma [PTCL], and diffuse large B cell lymphoma [DLBCL]), Solid tumors (eg, NSCLC, HNSCC, and melanoma)
- Status
- active
- Trials
- 1